Security
Redhill Biopharma Ltd. American Depositary Shares · RDHL
RDHLNASDAQotherCurrentCIK 1553846Updated Oct 14, 2026
RDHL price & chart
Loading TradingView…
NASDAQ:RDHL on TradingView ↗About the company
We are a specialty biopharmaceutical company, primarily focused on GI, infectious diseases and oncology. Our primary goal is to become a leading specialty biopharmaceutical company.
In the news
Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet ↗
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement ↗
Recent filings
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Profit or LossUSD | -8,268,000Source | 23,916,000Source | -71,669,000Source | -97,744,000Source |
| Additional Financial Items | ||||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | 52,000Source | 31,930,000Source | -2,845,000Source | -3,021,000Source |
| AdjustmentsForFinanceCostsUSD | — | — | 958,000Source | — |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableUSD | -2,110,000Source | -952,000Source | -7,434,000Source | 111,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 665,000Source | 1,647,000Source | 5,675,000Source | 10,212,000Source |
| IncreaseDecreaseInWorkingCapitalUSD | -2,053,000Source | 15,619,000Source | -8,008,000Source | 1,153,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 636,000Source | 1,175,000Source | 1,475,000Source | 1,683,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 9,567,000Source | 16,219,000Source | 28,586,000Source | 32,365,000Source |
| Total RevenueUSD | 8,043,000Source | 6,530,000Source | 61,800,000Source | 85,757,000Source |
| Additional Financial Items | ||||
| BasicEarningsLossPerShareUSD per share | 0Source | 0.01Source | -0.12Source | -0.21Source |
| DepreciationRightofuseAssetsUSD | 521,000Source | 1,276,000Source | 1,869,000Source | 1,890,000Source |
| DilutedEarningsLossPerShareUSD per share | 0Source | 0.01Source | -0.12Source | -0.21Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD | 665,000Source | — | — | — |
| FinanceCostsUSD | 2,056,000Source | 9,605,000Source | 42,387,000Source | 16,660,000Source |
| FinanceIncomeUSD | 8,401,000Source | 20,889,000Source | 13,562,000Source | 51,000Source |
| GrossProfitUSD | 4,851,000Source | 3,071,000Source | 28,463,000Source | 36,351,000Source |
| ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillUSD | — | — | 0Source | — |
| InterestExpenseOnLeaseLiabilitiesUSD | 55,000Source | 367,000Source | 430,000Source | 397,000Source |
| OtherFinanceCostUSD | 473,000Source | 61,000Source | 56,000Source | 65,000Source |
| OtherIncomeUSD | — | 210,000Source | — | — |
| OtherOperatingIncomeExpenseUSD | -2,359,000Source | 44,064,000Source | — | — |
| PostemploymentBenefitExpenseDefinedContributionPlansUSD | 156,000Source | 206,000Source | 261,000Source | 285,000Source |
| ProfitLossFromOperatingActivitiesUSD | -14,613,000Source | 12,632,000Source | -42,844,000Source | -81,135,000Source |
| ResearchAndDevelopmentExpenseUSD | 1,588,000Source | 3,528,000Source | 7,279,000Source | 29,498,000Source |
Offerings
Registration 333-297223
Registration 333-292528
Registration 333-288324
Filing attachments
rdhl-20260630xex99d2.htm · 6-K · 2026-09-30
Table of Contents Exhibit 99.2 REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2026 Table of Contents REDHILL BIOPHARMA LTD. CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION (UNAUDITED) June 30, 2026 TABLE OF CONTENTS UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 2026, IN U.S. DOLLARS: Page ────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗rdhl-ex99d1.htm · 6-K · 2026-09-30
Exhibit 99.1 Press Release RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results Executing a full strategic portfolio reset, RedHill is now a stronger commercial entity with Rebyota® and Clenpiq®, two established FDA-approved gastrointestinal (GI) brands that generated $37.5 million in 2025 net sales under Ferring Pharmaceuticals (“Ferring”), an advanced late-stage pipeline and a fully-controlled commercial infrastructure with capacity for portfolio expansio…
Read attachment ↗ex107.htm · F-3 · 2026-07-02
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 REDHILL BIOPHARMA LTD. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Amount Registered Proposed Maximum Offering Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee …
Read attachment ↗ex107.htm · S-8 · 2026-01-22
Calculation of Filing Fee Tables S-8 RedHill Biopharma Ltd. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee ──────────────────────────────────…
Read attachment ↗